Dermira (DERM) Received H.C. Wainwright’s Coverage; Alibaba Group Holding Limited American Depositary (BABA) Shorts Increased By 1.36%

Dermira, Inc. (NASDAQ:DERM) Logo

The research firm H.C. Wainwright has has initiated coverage on Dermira (NASDAQ:DERM)‘s stock, rating it a “Buy” while giving it the target price at $13.

Alibaba Group Holding Limited American Depositary (NYSE:BABA) had an increase of 1.36% in short interest. BABA’s SI was 106.38 million shares in February as released by FINRA. Its up 1.36% from 104.95M shares previously. With 24.20M avg volume, 4 days are for Alibaba Group Holding Limited American Depositary (NYSE:BABA)’s short sellers to cover BABA’s short positions. The SI to Alibaba Group Holding Limited American Depositary’s float is 12%. The stock increased 0.41% or $0.69 during the last trading session, reaching $169.4. About 8.66 million shares traded. Alibaba Group Holding Limited (NYSE:BABA) has declined 13.21% since February 14, 2018 and is downtrending. It has underperformed by 13.21% the S&P500. Some Historical BABA News: 07/05/2018 – BABA: It’s said that police are investigating bribery of #Alibaba staff. Some are taking bribes via #btc #eth; 19/03/2018 – Alibaba to invest additional $2bn in Lazada; 10/04/2018 – ANT FINANCIAL’S VALUATION SEEN SURGING TO ABOUT $150 BILLION AFTER LATEST FUNDRAISING; 02/04/2018 – Alibaba will buy Chinese food delivery app Ele.me; 19/04/2018 – Alibaba Signs Up to Help Out Thailand; 31/05/2018 – ALIBABA-BACKED WEWORK RIVAL IS SAID TO SEEK NEW FUNDING ROUND; 13/03/2018 – Unilever Enters into New Strategic Co-operation with Alibaba; 09/04/2018 – SEMTECH – ALIBABA CLOUD AND ZHEJIANG PROVINCIAL COMPANY OF CHINA UNICOM JOINTLY DEPLOYED PRE-COMMERCIAL SERVICE FOR IOT BASED ON LORA TECHNOLOGY; 28/05/2018 – Alibaba Health Information Technology: To Acquire Alibaba Holding Unit Ali JK Medical Products for HK$10.6 Billion; 29/05/2018 – ALIBABA GROUP HOLDING LTD – REACHED DEAL TO SELL CERTAIN HEALTHCARE CATEGORIES FROM TMALL PHARMACY TO ALIBABA HEALTH INFORMATION TECHNOLOGY LTD

Among 13 analysts covering Alibaba Group Holding (NYSE:BABA), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alibaba Group Holding had 18 analyst reports since August 16, 2018 according to SRatingsIntel. As per Friday, August 24, the company rating was maintained by JP Morgan. The firm has “Buy” rating by M Partners given on Tuesday, November 13. The firm has “Buy” rating by UBS given on Friday, August 24. UBS maintained the stock with “Buy” rating in Monday, November 5 report. SunTrust maintained it with “Buy” rating and $180 target in Friday, November 2 report. The rating was maintained by Raymond James with “Strong Buy” on Thursday, August 16. As per Friday, August 24, the company rating was maintained by Robert W. Baird. UBS maintained the shares of BABA in report on Friday, October 12 with “Buy” rating. The company was maintained on Wednesday, October 10 by KeyBanc Capital Markets. KeyBanc Capital Markets maintained it with “Overweight” rating and $203 target in Monday, November 5 report.

More notable recent Alibaba Group Holding Limited (NYSE:BABA) news were published by: Seekingalpha.com which released: “Alibaba: Still Cheap Even After Earnings Rally – Seeking Alpha” on February 12, 2019, also Seekingalpha.com with their article: “Alibaba Q3 2018 Earnings Preview – Seeking Alpha” published on January 29, 2019, Benzinga.com published: “Alibaba (NYSE:BABA) Analysts Stay Bullish After Q3 Print – Benzinga” on February 04, 2019. More interesting news about Alibaba Group Holding Limited (NYSE:BABA) were released by: Benzinga.com and their article: “Bullish SunTrust Previews Alibaba’s Q3 Print (NYSE:BABA) – Benzinga” published on January 28, 2019 as well as Seekingalpha.com‘s news article titled: “Analysts adjust Alibaba targets on earnings – Seeking Alpha” with publication date: January 31, 2019.

Alibaba Group Holding Limited, through its subsidiaries, operates as an online and mobile commerce firm in the People's Republic of China and internationally. The company has market cap of $439.12 billion. The firm operates in four divisions: Core Commerce, Cloud Computing, Digital Media and Entertainment, and Innovation Initiatives and Others. It has a 48.44 P/E ratio. It operates Taobao Marketplace, a mobile commerce destination; Tmall, a third-party platform for brands and retailers; Rural Taobao program that enables rural residents and businesses to sell agricultural products to urban consumers; Juhuasuan, a sales and marketing platform for flash sales; Alibaba.com, an online wholesale marketplace; Alitrip, an online travel booking platform; 1688.com, an online wholesale marketplace; and AliExpress, a consumer marketplace.

Since October 19, 2018, it had 0 insider purchases, and 1 sale for $55,000 activity. 4,000 shares were sold by Fust Matthew K, worth $55,000.

The stock decreased 2.43% or $0.18 during the last trading session, reaching $7.24. About 909,339 shares traded or 37.70% up from the average. Dermira, Inc. (NASDAQ:DERM) has declined 56.32% since February 14, 2018 and is downtrending. It has underperformed by 56.32% the S&P500. Some Historical DERM News: 24/05/2018 – DERMIRA:SUFFICIENT CAP FOR OPS TO MID-’20 EX-LEBRIKIZUMAB COSTS; 29/05/2018 – UCB Announces the Approval of CIMZIA(R) (certolizumab Pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S; 22/03/2018 – CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S; 10/04/2018 – Dermira at Deutsche Bank Health Care Conference May 8; 21/04/2018 – DJ Dermira Inc, Inst Holders, 1Q 2018 (DERM); 03/05/2018 – DERMIRA INC DERM.O – QTRLY SHR LOSS $1.42; 07/05/2018 – Dermira at Deutsche Bank Health Care Conference Tomorrow; 15/05/2018 – Adage Capital Partners GP Buys New 2.4% Position in Dermira; 05/03/2018 – #2 — Watch out below: Dermira axes acne drug after a catastrophic PhIII failure $DERM; 14/05/2018 – Fidelity Adds Magellan Health, Exits Dermira, Cuts Amgen

Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on February, 28. They expect $-1.80 EPS, down 34.33% or $0.46 from last year’s $-1.34 per share. After $-1.58 actual EPS reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts 13.92% negative EPS growth.

Investors sentiment decreased to 0.96 in 2018 Q3. Its down 0.02, from 0.98 in 2018Q2. It turned negative, as 22 investors sold Dermira, Inc. shares while 27 reduced holdings. 20 funds opened positions while 27 raised stakes. 35.10 million shares or 4.07% more from 33.73 million shares in 2018Q2 were reported. Wellington Management Ltd Liability Partnership stated it has 4.59 million shares. Jacobs Levy Equity invested 0% of its portfolio in Dermira, Inc. (NASDAQ:DERM). Bancorp Of Montreal Can has invested 0% in Dermira, Inc. (NASDAQ:DERM). Platinum Invest Mngmt owns 116,325 shares for 0.04% of their portfolio. Adage Cap Partners Grp Llc holds 2.00 million shares. Highland Cap Ltd Partnership invested in 0.03% or 44,740 shares. Sectoral Asset holds 0.05% of its portfolio in Dermira, Inc. (NASDAQ:DERM) for 41,902 shares. Voya Investment Mngmt Ltd Llc reported 0.03% in Dermira, Inc. (NASDAQ:DERM). Rock Springs Cap Mngmt Limited Partnership owns 600,000 shares or 0.24% of their US portfolio. Swiss Natl Bank reported 0% of its portfolio in Dermira, Inc. (NASDAQ:DERM). Aperio Group Inc Limited Liability Co holds 25,444 shares. Ameritas Investment accumulated 3,345 shares or 0% of the stock. Amer Interest Group Inc reported 23,099 shares or 0% of all its holdings. Quantbot Lp stated it has 0% in Dermira, Inc. (NASDAQ:DERM). Rhumbline Advisers invested 0% in Dermira, Inc. (NASDAQ:DERM).

More notable recent Dermira, Inc. (NASDAQ:DERM) news were published by: Seekingalpha.com which released: “Almirall in-licenses Dermira’s European rights to Lebrikizumab – Seeking Alpha” on February 12, 2019, also Benzinga.com with their article: “Benzinga’s Top Upgrades, Downgrades For January 17, 2019 – Benzinga” published on January 17, 2019, Benzinga.com published: “44 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” on February 12, 2019. More interesting news about Dermira, Inc. (NASDAQ:DERM) were released by: Benzinga.com and their article: “58 Biggest Movers From Yesterday – Benzinga” published on February 13, 2019 as well as Globenewswire.com‘s news article titled: “Dermira Reports Third Quarter 2018 Financial Results Nasdaq:DERM – GlobeNewswire” with publication date: November 07, 2018.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company has market cap of $304.96 million. The company??s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It currently has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

Dermira, Inc. (NASDAQ:DERM) Institutional Positions Chart